Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study.
about
Breast cancer and sexual functionMultidisciplinary overview of vaginal atrophy and associated genitourinary symptoms in postmenopausal womenImmunolocalization of steroidogenic enzymes in the vaginal mucous of Galea spixii during the estrous cycle.A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapyInterventions to address sexual problems in people with cancerCaring for the breast cancer survivor's health and well-being.Breast cancer, aromatase inhibitor therapy, and sexual functioning: a pilot study of the effects of vaginal testosterone therapyAdvances in pharmacotherapy for treating female sexual dysfunction.Improving patients' understanding of terms and phrases commonly used in self-reported measures of sexual function.An update on drugs for the treatment of menopausal symptoms.Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue.Vaginal Estrogen Therapy for Patients with Breast Cancer.The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI.An update on the pharmacological management of female sexual dysfunction.Androgen therapy in women, beyond libido.Treatment of vaginal atrophy.Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.Management of menopause in women with breast cancer.Safety of aromatase inhibitor therapy in breast cancer.Vaginal Health During Breast Cancer Treatment.Management of Potential Long-Term Toxicities in Breast Cancer Patients.Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy.Effects of long-term high dose testosterone administration on vaginal epithelium structure and estrogen receptor-α and -β expression of young women.Sexual function and sex hormones in breast cancer patients.A randomized, double-blind, crossover trial comparing a silicone- versus water-based lubricant for sexual discomfort after breast cancer.Female Sexual Dysfunction and Premature Menopause with Focus on Women’s Wording
P2860
Q26773714-AE67E87E-FA01-408E-9682-5475B415312BQ26828795-CD770ED9-A224-4C94-9C65-40866C42E01EQ33602152-C08AE231-B3BC-4544-808C-0C40815F75FBQ33605919-C1483D4E-A9FE-4E96-82BF-5617785CD06BQ33840155-1679BB01-9BD3-4694-BF29-C4C0EC92F477Q34031251-0782E3E5-DC9B-4E60-BEA5-00857AF7F40EQ34286594-DE723B25-F6C9-4E12-BABD-182E36DAA28DQ34465301-69BB3E84-90F2-4D10-AFB2-1D523D99DBB1Q34590345-F2C9FBB2-205C-42FA-91AE-9C765B39A98FQ35784054-6619C17F-A509-4A1F-8746-7E075EC1964FQ35824414-3CDE3246-2613-4A39-9254-C9C2E64CB132Q37389691-B9F9923B-6805-4BA5-AEFB-B23FCBA8C471Q38011784-AA75EB5D-CEB9-4023-B016-3BEF44DBAB0BQ38044019-7C791F82-BE6B-4616-99D1-29617B679316Q38104425-12C2AD96-F822-4112-BDB9-0F50A4525430Q38193877-07AF443F-C42E-49AF-BDD8-60826A55D888Q38232774-92697786-3E84-48E6-AB63-1518AC6DC556Q38298951-5C26813C-12C5-49CD-B171-838A5AAD5A99Q38522924-728ACEEB-C94C-4299-8025-28DC87A9EF34Q38807445-7609DDE2-B7B3-4AB1-8B12-385E15A5A481Q39305824-41FBB9AB-9B92-440D-A524-01CBA3BCD9EFQ45898328-2DF99744-94D6-4CC1-9FFF-05B9DCCF10ABQ45899500-188514EB-6F62-4E18-8F31-14276F7C7B92Q47579508-454C519F-87A6-4388-B333-15D96857C0C5Q53779463-5BFEB876-6CFE-4950-B41A-330720AA3F62Q57345846-63D40373-83DC-4B5F-B65D-0F23EAAE1BAD
P2860
Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Topical testosterone for breas ...... nhibitors: a phase I/II study.
@ast
Topical testosterone for breas ...... nhibitors: a phase I/II study.
@en
type
label
Topical testosterone for breas ...... nhibitors: a phase I/II study.
@ast
Topical testosterone for breas ...... nhibitors: a phase I/II study.
@en
prefLabel
Topical testosterone for breas ...... nhibitors: a phase I/II study.
@ast
Topical testosterone for breas ...... nhibitors: a phase I/II study.
@en
P2093
P2860
P1433
P1476
Topical testosterone for breas ...... inhibitors: a phase I/II study
@en
P2093
Charles D Maclean
Hyman Muss
Julia Johnson
Laurence Demers
Marie Wood
Sabrina Witherby
Sharon Mount
P2860
P304
P356
10.1634/THEONCOLOGIST.2010-0435
P577
2011-03-08T00:00:00Z